Bioatla (BCAB) Aktsia Kursus

BioAtla develops antibody-based therapeutics for solid tumor cancer, focusing on conditionally active biologics (CAB) antibody-drug conjugates (ADCs). Its lead product BA3011 targets AXL, a protein kinase receptor, while BA3021 targets ROR2, a receptor tyrosine kinase. BA3071 is a CAB anti-CTLA-4 antibody for multiple solid tumors including renal cell carcinoma and melanoma, and BA3182 uses Dual-CAB technology for adenocarcinoma treatment. The company generates revenue through the development and commercialization of these product candidates, targeting oncology treatment markets with specific therapeutic approaches. BioAtla's product pipeline includes BA3011, BA3021, BA3071, and BA3182, each addressing distinct cancer targets. The company focuses on developing novel therapeutics rather than selling existing products, with BA3011 as its lead candidate. Revenue is expected from future partnerships, licensing agreements, or eventual product sales once clinical development progresses to later stages. The company's business model centers on advancing its pipeline through clinical trials, with potential revenue streams from biopharmaceutical partnerships and product launches. BA3071 targets multiple solid tumor indications, including NSCLC and hepatocellular carcinoma, while BA3182 is designed for advanced adenocarcinoma. BioAtla's focus on CAB technology differentiates its approach in the oncology space.